MDM2: The ups and downs

Molecular Medicine

Volumn 5, Issue 2, 1999, Pages 71-83

  Juven Gershon, Tamar ^a   Oren, Moshe ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; DNA DEPENDENT PROTEIN KINASE; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN; RIBOSOME PROTEIN;

APOPTOSIS; CANCER GENETICS; CELL CYCLE; CELL DIFFERENTIATION; CELL TRANSFORMATION; COMPLEX FORMATION; DNA DAMAGE; GENE OVEREXPRESSION; HUMAN; MULTIGENE FAMILY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SHORT SURVEY;

EID: 0032952004     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03402141     Document Type: Short Survey

References (110)

1. Piette J, Ned H, Marechal V. (1997) Mdm2: keeping p53 under control. Oncogene 15: 1001-1010.
2. Momand J, Zambetti GP. (1997) Mdm-2: "bis brother" of p53. J. Cell. Biochem. 64: 343-352.
3. Lozano G, Montes De Oca Luna R. (1998) MDM2 function, Biochem. Biophys. Acta 1377: M55-59.
4. Cahilly-Snyder L, Yang FT, Francke U, George DL. (1987) Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat. Cell Mol. Genet. 13: 235-244.
5. Fakharzadeh SS, Trusko SP, George DL. (1991) Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10: 1565-1569.
6. Finlay CA. (1993) The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Bid. 13: 301-306.
7. Lundgren K, Montes De Oca Luna R, McNeill YB, et al. (1997) Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev. 11: 714-725.
8. Momand J, Jung D, Wilczynski S, Niland J. (1998) The MDM2 gene amplification database. Nucl. Acids Res. 26: 3453-3459.
9. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas [sec comments]. Nature 358: 80-83.
10. Leach FS, Tokino T, Meltzer P, et al. (1993) p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 2231-2234.
11. Cordon-Cardo C, Latres E, Drobnjak M, et al. (1994) Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54: 794-799.
12. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. (1993) MDM2 gene amplification in metastatic osteosarcoma. Cancer Res. 53: 16-18.
13. Shibagaki I, Tanaka H, Shimada Y, et al. (1995) p53 mutation, Murine Double Minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma. Clin. Cancer Res. 1: 769-773.
14. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. (1993) Amplification and overex-pression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 53: 2736-2739.
15. Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS, Collins VP. (1994) Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res. 54: 4299-4303.
16. Corvi R, Savelyeva L, Breit S, et al. (1995) Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. Oncogene 10: 1081-1086.
17. Landers JE, Haines DS, Strauss JR, George DL. (1994) Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 9: 2745-2750.
18. Landers JE, Cassel SL, George DL. (1997) Translalional enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res. 57: 3562-3568.
19. Wurl P, Meye A, Schmidt H, et al. (1998) High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene 16: 1183-1185.
20. Oison DC, Marechal V, Momand J, Chen J, Romocki C, Levine AJ. (1993) Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 8: 2353-2360.
21. Haines DS, Landers JE, Engle LJ, George DL. (1994) Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol. Cell. Biol. 14: 1171-1178.
22. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J. (1996) Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat. Med. 2: 912-917.
23. Marechal V, Elenbaas B, Taneyhill L, et al. (1997) Conservation of structural domains and biochemical activities of the MDM2 protein from Xenopus laevis. Oncogene 14: 1427-1433.
24. Elenbaas B, Dobbelstein M, Roth J, Shenk T, Levine AJ. (1996) The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol. Med. 2: 439-451.
25. Marechal V, Elenbaas B, Piette J, Nicolas JC, Levine AJ. (1994) The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol. Cell. Biol. 14: 7414-7420.
26. Boddy MN, Freemont PS, Borden KL. (1994) The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger. Trends Biochem. Sci. 19: 198-199.
27. Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ. (1998) Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17: 554-564.
28. Chen L, Marechal V, Moreau J, Levine AJ, Chen J. (1997) Proteolytic cleavage of the mdm2 oncoprotein during apoptosis. J. Biol. Chem. 272: 22966-22973.
29. Erhardt P, Tomaselli KJ, Cooper GM. (1997) Identification of the MDM2 oncoprotein as a substrate for CPP32-like apoptotic proteases. J. Biol. Chem. 272: 15049-15052.
30. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. (1992) The mdm-2 oncogene product forms a complex with the p53 prolein and inhibits p53-niediated transactivation. Cell 69: 1237-1245.
31. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857-860.
32. Chen J, Lin J, Levine AJ. (1995) Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med. 1: 142-152.
33. Barak Y, Juven T, Haffner R, Oren M. (1993) mdm2 expression is induced by wild-type p53 activity. EMBO J. 12: 461-468.
34. Juven T, Barak Y, Zauberman A, George DL, Oren M. (1993) Wild-type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8: 3411-3416.
35. Wu X, Bayle JH, Olson D, Levine AJ. (1993) The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7: 1126-1132.
36. Barak Y, Gottlieb E, Juven-Gershon T, Oren M. (1994) Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Gems Dev. 8: 1739-1749.
37. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M. (1995) A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucl. Acids Res. 23: 2584-2592.
38. Picksley SM, Lane DP. (1993) The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays 15: 689-690.
39. Chen J, Marechal V, Levine AJ. (1993) Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13: 4107-4114.
40. Lin J, Chen J, Elenbaas B, Levine AJ. (1994) Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8: 1235-1246.
41. Picksley SM, Vojtesek B, Sparks A, Lane DP. (1994) Immunochemical analysis of the interaction of p53 with MDM2-fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 9: 2523-2529.
42. Thut CJ, Goodrich JA, Tjian R. (1997) Repression of p53-mediatcd transcription by MDM2: a dual mechanism. Genes Dev, 11: 1974-1986.
43. Leng P, Brown DR, Deb S, Deb SP. (1995) Human oncoprotein MDM2 interacts with the TATA-binding protein in vitro and in vivo. Int. J. Oncology 6: 251-259.
44. Haupt Y, Maya R, Kazaz A, Oren M. (1997) Mdm2 promotes the rapid degradation of p53. Nature 187: 296-299.
45. Kubbutat MH, Jones SN, Vousden KH. (1997) Regulation of p53 stability by Mdm2. Nature 387: 299-303.
46. Bottger A, Bottger V, Sparks A, Liu WL, Howard SF, Lane DP. (1997) Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7: 860-869.
47. Honda R, Tanaka H, Yasuda H. (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420: 25-27.
48. Perry ME, Piette J, Zawadzki JA, Harvey D, Levine AJ. (1993) The mdm-2 gene is induced in response to UV light in a p53-dcpendent manner. Proc. Natl. Acad. Sci. U.S.A. 90: 11623-11627.
49. Wu L, Levine AJ. (1997) Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Mol. Med. 3: 441-451.
50. Saucedo LJ, Carstens BP, Seavey SE, Albee LD, Perry ME. (1998) Regulation of transcriptional activation of mdm2 gene by p53 in response to UV radiation. Cell Growth Differ. 9: 119-130.
51. Chen CY, Oliner JD, Zhan Q, Fornace AJ, Vogelstein B, Kastan MB. (1994) Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci. U.S.A. 91: 2684-2688.
52. Price BD, Park SJ. (1994) DNA damage increases the levels of MDM2 messenger RNA in wtp53 human cells. Cancer Res. 54: 896-899.
53. Chang YC, Lee YS, Tejima T, et al. (1998) mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ. 9: 79-84.
54. Kussie PH, Gorina S, Marechal V, et al. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953.
55. Marston NJ, Jenkins JR, Vousden KH. (1995) Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6. Oncogene 10: 1709-1715.
56. Kubbutat M, Ludwig RL, Ashcroft M, Vousden KH. (1998) Regulation of Mdm2-directed degradation by the C terminus of p53. Mol. Cell Biol. 18: 5690-5698.
57. Prives C. (1998) Signaling to p53: breaking the MDM2-p53 circuit. Cell 95: 5-8.
58. Freedman DA, Levine AJ. (1998) Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18: 7288-7293.
59. Chen J, Wu X, Lin J, Levine AJ. (1996) mdm-2 inhibits the GI arrest and apoplosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol. 16: 2445-2452.
60. Haupt Y, Barak Y, Oren M. (1996) Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 15: 1596-1606.
61. Momand J, Zambetti GP. (1996) Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics. Oncogene 12: 2279-2289.
62. Montes De Oca Luna R, Wagner DS, Lozano G. (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206.
63. Jones SN, Roe AE, Donehower LA, Bradley A. (1995) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208.
64. Shieh SY, Ikeda M, Taya Y, Prives C. (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334.
65. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB. (1997) DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 11: 3471-3481.
66. Banin S, Moyal L, Shieh S, et al. (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281: 1674-1677.
67. Canman CE, Lim DS, Cimprich KA, et al. (1998) Activation of the ATM Kinase by Ionizing Radiation and Phosphorylation of p53. Science 281: 1677-1679.
68. Woo RA, McLure KG, Lees-Miller SP, Rancourt DE, Lee PW. (1998) DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. Nature 394: 700-704.
69. Barak Y, Oren M. (1992) Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J. 11: 2115-2121.
70. Guerra B, Gotz C, Wagner P, Montenarh M, Issinger OG. (1997) The carboxy terminus of p53 mimics the polylysine effect of protein kinase CK2-catalyzed MDM2 phosphorylation. Oncogene 14: 2683-2688.
71. Mayo LD, Turchi JJ, Berberich SJ. (1997) Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res. 57: 5013-5016.
72. Henning W, Rohaly G, Kolzau T, Knippschild U, Maacke H, Deppert W. (1997) MDM2 is a target of simian virus 40 in cellular transformation and during lytic infection. J. Virol. 71: 7609-7618.
73. Bottger V, Bottger A, Howard SF, et al (1996) Identification of novel mdm2 binding peptides by phage display. Oncogene 13: 2141-2147.
74. Bottger A, Bottger V, Garcia EC, et al. (1997) Molecular characterization of the hdm2-p53 interaction. J. Mol. Biol. 269: 744-756.
75. Chen L, Agrawal S, Zhou W, Zhang R, Chen J. (1998) Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc. Natl. Acad. Sci. U.S.A. 95: 195-200.
76. Midgley CA, Lane DP. (1997) p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15: 1179-1189.
77. Blaydes JP, Wynford-Thomas D. (1998) The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2. Oncogene 16: 3317-3322.
78. Dahl AM, Beverley PC, Stauss HJ. (1996) A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. J. Immunol. 157: 239-246.
79. Xiao ZX, Chen J, Levine AJ, et al. (1995) Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694-698.
80. Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue N, Kouzarides T. (1995) Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375: 691-694.
81. Hsieh JK, Fredersdorf S, Kouzarides T, Martin K, Lu X. (1997) E2F1-induced apoplosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev. 11: 1840-1852.
82. Kowalik TF, DeGregori J, Leone G, Jakoi L, Nevins JR. (1998) E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ. 9: 11 3-118.
83. O'Connor DJ, Lam EW, Griffin S, et al. (1995) Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1. EMBO J. 14: 6184-6192.
84. Sorensen TS, Girling R, Lee CW, Gannon J, Bandara LR, La Thangue N. (1996) Functional interaction between DP-1 and p53. Mol. Cell. Biol. 16: 5888-5895.
85. Juven-Gershon T, Shifman O, Unger T, Elkeles A, Haupt Y, Oren M. (1998) The Mdm2 oncoprotein interacts with the cell fate regulator numb. Mol. Cell. Biol. 18: 3974-3982.
86. Zeng X, Chen L, Jost CA, et al. Mdm2 suppresses p73 function without promoting p73 degradation. Mol. Cell. Biol. (in press).
87. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000.
88. Pomerantz J, Schreiber AN, Liegeois NJ, et al. (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723.
89. Zhang Y, Xiong Y, Yarbrough WG. (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734.
90. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ, (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Prof. Natl. Acad. Sci. U.S.A. 95: 8292-8297.
91. Stott FJ, Bates S, James MC, et al. (1998) The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17: 5001-5014.
92. Bates S, Phillips AC, Clark PA, et al. (1998) p14ARF links the tumour suppressors RB and p53. Nature 395: 124-125.
93. de-Stanchina E, McCurrach ME, Zindy F, et al. (1998) E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 12: 2434-2442.
94. Zindy F, Eischen CM, Randle DH, et al. (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortaization. Genes Dev. 12: 2424-2433.
95. Palmero I, Pantoja C, Serrano M. (1998) p19ARF links (he tumour suppressor p53 to Ras. Nature 395: 125-126.
96. Grossman SR, Perez M, Kung AL, et al. (1998) p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell 2: 405-415.
97. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM. (1997) Binding and modulation of p53 by p300/CBP coactivators. Nature 387: 823-827.
98. Gu W, Shi XL, Roeder RG. (1997) Synergistic activation of transcription by CBF and p53. Nature 387: 819-823.
99. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K. (1997) Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89: 1175-1184.
100. Scolnick DM, Chehab NH, Stavridi ES, et al. (1997) CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res. 57: 3693-3696.
101. Thomas A, White E. (1998) Suppression of the p300-dependent mdm2 negative-feedback loop induces the p53 apoptotic function. Genes Dev. 12: 1975-1985.
102. McMasters KM, Montes De Oca Luna R, Pena JR, Lozano G. (1996) mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts. Oncogene 13: 1731-1736.
103. Jones SN, Sands AT, Hancock AR, et al. (1996) The tumorigenic potential and cell growth characteristics of p53-defident cells are equivalent in the presence or absence of Mdm2. Proc. Nail. Acad. Sci. U.S.A. 93: 14106-14111.
104. Dubs-Poterszman M, Tocque B, Wasylyk B. (1995) MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest, Oncogene 11: 2445-2449.
105. Sun P, Dong P, Dai K, Hannon GJ, Beach D. (1998) p53-independent role of MDM2 in TGFβ1 resistance. Science 282: 2270-2272.
106. Shvarts A, Steegenga WT, Riteco N, et al. (1996) MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J. 15: 5349-5357.
107. Leveillard T, Gorry P, Niederreither K, Wasylyk B. (1998) MDM2 expression during mouse embryogcnesis and the requirement of p53. Mech, Dev. 74: 189-193.
108. Fiddler TA, Smith L, Tapscott SJ, Thayer MJ. (1996) Amplification of MDM2 inhibits MyoD-mediated myogenesis. Mol. Cell. Biol. 16: 5048-5057.
109. Brown DR, Thomas CA, Deb SP. (1998) The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J. 17: 2513-2525.
110. Shvarts A, Bazuine M, Dekker P, et al. (1997) Isolation and identification of the human homolog of a new p53-binding protein, Mdmx. Genomics 43: 34-42.